Actually, it was NP who mentioned (quite informally and off-the-cuff maybe two calls ago) $100B of annual peak sales if cancer is approved.

Back of the Envelope:

$100B Sales [divided by] 700M Shares [equals] $142.85 per Share

Now, that's looks to be a Revenue number and not an Earnings number.

So, let's halve that peak sales number:

$50B Earnings [divided by] 700M Shares [equals] $71.42 per Share

But that number does not include a P/E ratio -- choose your favorite multiple.

It's impossible to know how much market research the small CYDY team conducted to arrive at that $100B number. Nor do we know what percentage of market penetration they have based it on.

Frankly, with so many potential indications in-the-air -- I don't know how anyone could arrive at a meaningful number at this time.